Showing results (191-200 of 389) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLEAkito Hata, Isamu Okamoto, Naoki Inui, et al.
Scientific Reports|September 19, 2019
<sup>18</sup>F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancerKazuki Takada, Gouji Toyokawa, Yasuto Yoneshima, et al.
Molecular Cancer Therapeutics|April 22, 2010
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibitionWataru Okamoto, Isamu Okamoto, Takeshi Yoshida, et al.
Biochemical and Biophysical Research Communications|March 8, 2011
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failureKoichi Azuma, Junji Tsurutani, Kazuko Sakai, et al.
Clinical Lung Cancer|November 17, 2020
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)Hajime Asahina, Kentaro Tanaka, Satoshi Morita, et al.
Drug Safety|October 19, 2017
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety ResultsTerufumi Kato, Takashi Seto, Makoto Nishio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2012
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancerJunko Tanizaki, Isamu Okamoto, Takafumi Okabe, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2020
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapyKazuki Takada, Shinkichi Takamori, Yasuto Yoneshima, et al.
Japanese Journal of Clinical Oncology|November 28, 2009
Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumorsIsamu Okamoto, Masaki Munakata, Masaki Miyazaki, et al.
Frontiers in Immunology|March 23, 2023
Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseasesKentaro Hata, Toyoshi Yanagihara, Keisuke Matsubara, et al.
Pageof 39